Laporan penilaian publik Eropa (EPAR) untuk obat-obatan manusia: Cometriq, cabozantinib, Tanggal otorisasi: 21/03/2014, Revisi: 32, Status: Diotorisasi
This is a summary of the European public assessment report (EPAR) for Cometriq.
KESHAV
Informasi obat, indikasi, dosis, dan keamanan yang terkait dengan produk yang tersedia saat ini.
This is a summary of the European public assessment report (EPAR) for Cometriq.
Opzelura is a medicine used for treating non-segmental vitiligo, a disease that causes patches of skin to lose colour on both sides of the body.
Kigabeq is a medicine for treating epilepsy in children between 1 month and 7 years of age.